Asset Details
Do you wish to reserve the book?
Identification of Therapeutic Candidates for Chronic Lymphocytic Leukemia from a Library of Approved Drugs
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Identification of Therapeutic Candidates for Chronic Lymphocytic Leukemia from a Library of Approved Drugs
Do you wish to request the book?
Identification of Therapeutic Candidates for Chronic Lymphocytic Leukemia from a Library of Approved Drugs
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Identification of Therapeutic Candidates for Chronic Lymphocytic Leukemia from a Library of Approved Drugs
2013
Overview
Chronic lymphocytic leukemia (CLL) is an adult lymphoid malignancy with a variable clinical course. There is considerable interest in the identification of new treatments, as most current approaches are not curative. While most patients respond to initial chemotherapy, relapsed disease is often resistant to the drugs commonly used in CLL and patients are left with limited therapeutic options. In this study, we used a luminescent cell viability assay based on ATP levels to find compounds that were potent and efficacious in killing CLL cells. We employed an in-house process of quantitative high throughput screening (qHTS) to assess 8 concentrations of each member of a 2,816 compound library (including FDA-approved drugs and those known to be bio-active from commercial suppliers). Using qHTS we generated potency values on each compound in lymphocytes donated from each of six individuals with CLL and five unaffected individuals. We found 102 compounds efficacious against cells from all six individuals with CLL (\"consensus\" drugs) with five of these showing low or no activity on lymphocytes from a majority of normal donors, suggesting some degree of specificity for the leukemic cells. To our knowledge, this is the first study to screen a drug library against primary CLL cells to identify candidate agents for anti-cancer therapy. The results presented here offer possibilities for the development of novel drug candidates for therapeutic uses to treat CLL and other diseases.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
Adenosine Triphosphate - metabolism
/ Adult
/ Aged
/ Antineoplastic Agents - pharmacology
/ B cells
/ Cancer
/ Cell Survival - drug effects
/ Chronic lymphocytic leukemia
/ Drugs
/ Female
/ High-Throughput Screening Assays
/ Humans
/ Leukemia
/ Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
/ Leukemia, Lymphocytic, Chronic, B-Cell - pathology
/ Male
/ Patients
